FDA mulls tougher standards on diabetes research

The FDA is taking a look at a fresh set of standards that demand new tests to determine if diabetes drugs elevate heart risks. Safety advocates sounded approving after seeing the FDA draft guidance that came out at the end of February. But investors have proven to be less thrilled. In one case, they sent the shares of Amylin down to a 30-month low after determining that the new rules could significantly delay final approval of a new drug.

"It is setting the stage for some harder times for diabetes drugs," says researcher Clifford Rosen. According to Rosen the message to drug companies is clear: "Be careful" to remember that blood sugar alone will not warrant an automatic approval.

- check out the report from Forbes

Suggested Articles

Removing the IRE1-alpha gene from beta cells in mouse models of Type 1 diabetes restored normal insulin production, scientists found.

Selectively targeting TGF-beta1 with Scholar Rock's SRK-181 overcame primary resistance to checkpoint inhibitor therapy in mice.

Enhertu produced a 55.6% objective response rate in HER2-positive non-small cell lung cancer patients in a phase 1 trial.